Value of Glycosylated Hemoglobin at 34 Weeks Gestation in the Prediction of Adverse Neonatal Outcome | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 16, Volume 69, Issue 2, October 2017, Pages 1880-1888 PDF (451.59 K) | ||
| Document Type: Original Article | ||
| DOI: 10.12816/0040617 | ||
| Authors | ||
| Hassan T. Khairy; Mohamed E. Mohamed; Sherif H. Hussain; Mohamed S. Al-Refaie | ||
| Department of Gynecology, Faculty of Medicine, Ain Shams University | ||
| Abstract | ||
| Background: Gestational diabetes is diabetes, or high blood sugar levels, that develops during pregnancy. It occurs in about 4% of all pregnancies. It is usually diagnosed in the later stages of pregnancy and often occurs in women who have no prior history of diabetes. Aim of the Work: To assess the predictive value of elevated glycosylated hemoglobin at 34 weeks’ gestation with adverse fetal outcome as regard fetal macrosomia and neonatal hypoglycemia. Patients and Methods: This prospective longitudinal cohort study included 98 pregnant women who were recruited from the obstetric outpatient clinic and department at Al-Galaa Teaching Hospital. Results: HbA1c ≥7.9 has sensitivity of 88.1% and specificity of 66.1%, in prediction of macrosomia and a sensitivity of91.9% and specificity of 63.9% in prediction of Hypoglycemia. Conclusion: HbA1c ≥7.9 has moderate diagnostic characteristics in prediction ofmacrosomia, and hypoglycemia, low diagnostic characteristics in prediction of RDS and NICU. Recommendations: Use of HbA1C is recommended for patients with GDM for screening, follow up and prediction of adverse neonatal outcomes. | ||
| Keywords | ||
| Glycosylated Hemoglobin; gestation; adverse neonatal outcome; Fetal Macrosomia | ||
|
Statistics Article View: 126 PDF Download: 352 |
||
